In addition, DFS markedly reduced TCF/LEF signaling activity in GBM TSs in a dose-dependent manner (Fig. 3F), as well as reducing the expression of cyclin D1 and cMyc, which are regulated by FOXM1/β-catenin forming a complex with the TCF/LEF transcription factor (Fig. 3G). The gene discussed is MYC; the disease is glioblastoma.